The authors wish to make the following corrections to this paper \[[@B1-cancers-12-00553]\]:

On page 14, in paragraph two of Chapter 4, Echoviruses, the sentence: "The United States, much of the European Union and Japan found a lack of experimental evidence to approve Rigvir in cancer treatment \[99\]" should be deleted.

On page 15, line one, the sentence: "One such retrospective study showed a statistically significant increase in 3-year survival of melanoma patients when treated with Rigvir post-surgery than surgery alone or with other immunomodulators \[97\]", should be changed to: "One such retrospective study showed a statistically significant 4.39--6.57-fold decrease in mortality of melanoma patients when treated with Rigvir post-surgery than surgery alone \[97\]".

On page 15, line three, the sentence: "For best efficacy, Rigvir is injected intratumourally rather than intramuscularly, increasing 5-year survival between 29.9% and 19.5% \[97\]" should be deleted.

On page 15, paragraph two, line seven, the sentence "In the case of the stage IV histiocytic sarcoma patient, Rigvir was administered as part of a therapeutic cocktail including multisite radiation therapy, doxorubicin, cyclophosphamide and helixor P" should read: "In the case of the stage IV histiocytic sarcoma patient, Rigvir was administered for about 2 years followed by multisite radiation therapy, doxorubicin, cyclophosphamide and helixor P."

On page 15, paragraph three, line two, the sentence "One patient with a basal cell carcinoma, a diagnosis with a median expected survival of five months, was treated with Rigvir post-surgery \[101\]" should read: "One patient with melanoma unknown primary brain metastasis, a diagnosis with a median expected survival of five months, was treated with Rigvir post-surgery \[101\]."

The authors would like to apologize for any inconvenience caused to the readers by these changes.
